Stoke Therapeutics
STOK
94 hedge funds and large institutions have $855M invested in Stoke Therapeutics in 2021 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 33 increasing their positions, 25 reducing their positions, and 16 closing their positions.
1,566% more capital inflows, than outflows
Capital inflows: $408M | Capital outflows: $24.5M
43.66% more ownership
Funds ownership: 52.67% → 96.33% (+44%)
32% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 25
25% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 16
4% more funds holding
Funds holding: 90 → 94 (+4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Octagon Capital Advisors
New York
|
+$11.6M |
| 2 |
Cowen and Company
New York
|
+$6.19M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$5.58M |
| 4 |
Ally Bridge Group
New York
|
+$4.41M |
| 5 |
Fort Point Capital Partners
San Francisco,
California
|
+$3.82M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Redmile Group
San Francisco,
California
|
-$3.23M |
| 2 |
State Street
Boston,
Massachusetts
|
-$2.81M |
| 3 |
Tekla Capital Management
Boston,
Massachusetts
|
-$2.52M |
| 4 |
Cormorant Asset Management
Boston,
Massachusetts
|
-$2.29M |
| 5 |
Renaissance Technologies
New York
|
-$2.11M |
STOK Hedge Fund Activity: Q4 2021 in Review
94 of the 6,522 institutional investors tracked by Wall St. Rank reported a position in Stoke Therapeutics (STOK) for Q4 2021, worth a combined $855M — up 74% from $492M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new STOK positions and 16 closed out — a net gain of 4 holders — while 33 added to existing stakes and 25 trimmed.
The largest buyer was Octagon Capital Advisors, adding an estimated $11.6M. The largest seller was Redmile Group, cutting an estimated $3.23M.
- 94 institutional investors held Stoke Therapeutics (STOK) as of Q4 2021, up from 90 in Q3 2021.
- Funds reported $855M of Stoke Therapeutics stock for Q4 2021, up 74% quarter-over-quarter.
- 20 funds opened new Stoke Therapeutics positions in Q4 2021 and 16 closed out, a net change of +4 holders.
- The largest Stoke Therapeutics buyer in Q4 2021 was Octagon Capital Advisors, an estimated $11.6M added.
- The largest Stoke Therapeutics seller in Q4 2021 was Redmile Group, an estimated $3.23M sold.
Based on aggregated 13F filings for Q4 2021.